Physician profile
Stephen A Renae
NPI 1841296670
$14,477.77
in general payments reported to CMS, 2019-2025
21 companies · $2,251 in 2025
The $2,251 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,154 · 2020: $1,103 · 2021: $1,362 · 2022: $1,554 · 2023: $2,792 · 2024: $3,262 · 2025: $2,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,304.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $5,990.47 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $4,906.40 | 2019-2025 | Biktarvy |
| Janssen Biotech, INC. | $688.72 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $530.85 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $485.53 | 2019-2025 | |
| Insmed, INC. | $395.68 | 2019-2025 | Arikayce, Brinsupri |
| Theratechnologies INC. | $379.03 | 2020-2025 | Trogarzo, Egrifta |
| Paratek Pharmaceuticals, INC. | $267.07 | 2024-2025 | Nuzyra |
| Janssen Scientific Affairs, LLC | $216.08 | 2019-2023 | Symtuza |
| Stryker Corporation | $141.14 | 2024 | |
| Emd Serono, INC. | $93.68 | 2023-2025 | Serostim |
| Melinta Therapeutics, LLC | $86.07 | 2019-2025 | Rezzayo, Kimyrsa |
| Cardinal Health 110 LLC | $62.36 | 2024 | |
| Shionogi INC | $57.90 | 2024 | Fetroja |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $28.17 | 2024 | Voquezna |
| Allergan, INC. | $27.55 | 2019 | |
| Hologic Sales and Service, LLC | $27.11 | 2024 | Aptima |
| La Jolla Pharmaceutical Company | $25.50 | 2023 | Xerava |
| Vyera Pharmaceuticals, LLC | $23.33 | 2020 | |
| Aspira Women'S Health INC | $16.65 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Renae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.